Intrinsic Therapeutics
is backed by leaders in healthcare venture capital.
Intrinsic Therapeutics, Inc. is a privately
owned company that was incorporated in February 2000 to
design, develop, manufacture and market medical devices
for use in treating spinal disorders.
In February 2000, Intrinsic completed
a series A financing with Spray Venture Partners. Intrinsic closed series
B in January 2001 for 7.5m with New Enterprise Associates
and Spray Venture Partners. A series C round was closed
in December 2002 for 25m with New Leaf Venture Partners and
New Enterprise Associates.
The latest round, series D, closed in August 2007 for 21m
including New Enterprise Associates, New Leaf Venture Partners
and Quilvest.
Funding raised through series D has been used to build Intrinsic
in the area of product development, testing, and attracting
talented individuals to build a strong company for the purpose
of conducting clinical trials and building a marketing and
sales initiative.
The company has a strong focus on building
for the future in the area of product and procedure development.
New
Leaf Venture Partners
New Leaf Venture Partners (formerly The
Sprout Group) is one of the oldest and largest venture
capital firms in the U.S. Since 1969, Sprout has helped finance
more than 300 companies with combined sales exceeding $40
billion and currently manages $3 billion in committed capital.
With offices in Menlo Park and New York, Sprout focuses on
helping to grow companies in the healthcare technology and
information technology sectors. Sprout Group is a venture
capital affiliate of Credit Suisse First Boston.
New Enterprise
Associates
Founded in 1978, NEA now manages $4.8 billion of capital,
concentrating on early stage companies in the areas of information
technology and medical sciences.
Spray Venture Partners
Founded in 1992, Spray provides funding and expertise for
emerging healthcare technology companies which seek to
develop, market and deploy innovative technologies to meet
major unmet healthcare needs.
|
